Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression

Marianela Candolfi, James F. Curtin, W. Stephen Nichols, A. K M G Muhammad, Gwendalyn D. King, G. Elizabeth Pluhar, Elizabeth A. McNiel, John R. Ohlfest, Andrew B. Freese, Peter F Moore, Jonathan Lerner, Pedro R. Lowenstein, Maria G. Castro

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

Although rodent glioblastoma (GBM) models have been used for over 30 years, the extent to which they recapitulate the characteristics encountered in human GBMs remains controversial. We studied the histopathological features of dog GBM and human xenograft GBM models in immune-deficient mice (U251 and U87 GBM in nude Balb/c), and syngeneic GBMs in immune-competent rodents (GL26 cells in C57BL/6 mice, CNS-1 cells in Lewis rats). All GBMs studied exhibited neovascularization, pleomorphism, vimentin immunoreactivity, and infiltration of T-cells and macrophages. All the tumors showed necrosis and hemorrhages, except the U87 human xenograft, in which the most salient feature was its profuse neovascularization. The tumors differed in the expression of astrocytic intermediate filaments: human and dog GBMs, as well as U251 xenografts expressed glial fibrillary acidic protein (GFAP) and vimentin, while the U87 xenograft and the syngeneic rodent GBMs were GFAP and vimentin+. Also, only dog GBMs exhibited endothelial proliferation, a key feature that was absent in the murine models. In all spontaneous and implanted GBMs we found histopathological features compatible with tumor invasion into the non-neoplastic brain parenchyma. Our data indicate that murine models of GBM appear to recapitulate several of the human GBM histopathological features and, considering their reproducibility and availability, they constitute a valuable in vivo system for preclinical studies. Importantly, our results indicate that dog GBM emerges as an attractive animal model for testing novel therapies in a spontaneous tumor in the context of a larger brain.

Original languageEnglish (US)
Pages (from-to)133-148
Number of pages16
JournalJournal of Neuro-Oncology
Volume85
Issue number2
DOIs
StatePublished - Nov 2007

Fingerprint

Glioblastoma
Heterografts
Vimentin
Neoplasms
Dogs
Rodentia
Glial Fibrillary Acidic Protein
Intermediate Filaments
Brain
Inbred C57BL Mouse
Necrosis
Animal Models
Macrophages
Hemorrhage
T-Lymphocytes

Keywords

  • CNS-1
  • Dog
  • GL26
  • Glioma
  • U251
  • U87

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. K. M. G., King, G. D., Pluhar, G. E., ... Castro, M. G. (2007). Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression. Journal of Neuro-Oncology, 85(2), 133-148. https://doi.org/10.1007/s11060-007-9400-9

Intracranial glioblastoma models in preclinical neuro-oncology : Neuropathological characterization and tumor progression. / Candolfi, Marianela; Curtin, James F.; Nichols, W. Stephen; Muhammad, A. K M G; King, Gwendalyn D.; Pluhar, G. Elizabeth; McNiel, Elizabeth A.; Ohlfest, John R.; Freese, Andrew B.; Moore, Peter F; Lerner, Jonathan; Lowenstein, Pedro R.; Castro, Maria G.

In: Journal of Neuro-Oncology, Vol. 85, No. 2, 11.2007, p. 133-148.

Research output: Contribution to journalArticle

Candolfi, M, Curtin, JF, Nichols, WS, Muhammad, AKMG, King, GD, Pluhar, GE, McNiel, EA, Ohlfest, JR, Freese, AB, Moore, PF, Lerner, J, Lowenstein, PR & Castro, MG 2007, 'Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression', Journal of Neuro-Oncology, vol. 85, no. 2, pp. 133-148. https://doi.org/10.1007/s11060-007-9400-9
Candolfi, Marianela ; Curtin, James F. ; Nichols, W. Stephen ; Muhammad, A. K M G ; King, Gwendalyn D. ; Pluhar, G. Elizabeth ; McNiel, Elizabeth A. ; Ohlfest, John R. ; Freese, Andrew B. ; Moore, Peter F ; Lerner, Jonathan ; Lowenstein, Pedro R. ; Castro, Maria G. / Intracranial glioblastoma models in preclinical neuro-oncology : Neuropathological characterization and tumor progression. In: Journal of Neuro-Oncology. 2007 ; Vol. 85, No. 2. pp. 133-148.
@article{f4cf10d2bb9a4e888310ea8489540ab8,
title = "Intracranial glioblastoma models in preclinical neuro-oncology: Neuropathological characterization and tumor progression",
abstract = "Although rodent glioblastoma (GBM) models have been used for over 30 years, the extent to which they recapitulate the characteristics encountered in human GBMs remains controversial. We studied the histopathological features of dog GBM and human xenograft GBM models in immune-deficient mice (U251 and U87 GBM in nude Balb/c), and syngeneic GBMs in immune-competent rodents (GL26 cells in C57BL/6 mice, CNS-1 cells in Lewis rats). All GBMs studied exhibited neovascularization, pleomorphism, vimentin immunoreactivity, and infiltration of T-cells and macrophages. All the tumors showed necrosis and hemorrhages, except the U87 human xenograft, in which the most salient feature was its profuse neovascularization. The tumors differed in the expression of astrocytic intermediate filaments: human and dog GBMs, as well as U251 xenografts expressed glial fibrillary acidic protein (GFAP) and vimentin, while the U87 xenograft and the syngeneic rodent GBMs were GFAP and vimentin+. Also, only dog GBMs exhibited endothelial proliferation, a key feature that was absent in the murine models. In all spontaneous and implanted GBMs we found histopathological features compatible with tumor invasion into the non-neoplastic brain parenchyma. Our data indicate that murine models of GBM appear to recapitulate several of the human GBM histopathological features and, considering their reproducibility and availability, they constitute a valuable in vivo system for preclinical studies. Importantly, our results indicate that dog GBM emerges as an attractive animal model for testing novel therapies in a spontaneous tumor in the context of a larger brain.",
keywords = "CNS-1, Dog, GL26, Glioma, U251, U87",
author = "Marianela Candolfi and Curtin, {James F.} and Nichols, {W. Stephen} and Muhammad, {A. K M G} and King, {Gwendalyn D.} and Pluhar, {G. Elizabeth} and McNiel, {Elizabeth A.} and Ohlfest, {John R.} and Freese, {Andrew B.} and Moore, {Peter F} and Jonathan Lerner and Lowenstein, {Pedro R.} and Castro, {Maria G.}",
year = "2007",
month = "11",
doi = "10.1007/s11060-007-9400-9",
language = "English (US)",
volume = "85",
pages = "133--148",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Intracranial glioblastoma models in preclinical neuro-oncology

T2 - Neuropathological characterization and tumor progression

AU - Candolfi, Marianela

AU - Curtin, James F.

AU - Nichols, W. Stephen

AU - Muhammad, A. K M G

AU - King, Gwendalyn D.

AU - Pluhar, G. Elizabeth

AU - McNiel, Elizabeth A.

AU - Ohlfest, John R.

AU - Freese, Andrew B.

AU - Moore, Peter F

AU - Lerner, Jonathan

AU - Lowenstein, Pedro R.

AU - Castro, Maria G.

PY - 2007/11

Y1 - 2007/11

N2 - Although rodent glioblastoma (GBM) models have been used for over 30 years, the extent to which they recapitulate the characteristics encountered in human GBMs remains controversial. We studied the histopathological features of dog GBM and human xenograft GBM models in immune-deficient mice (U251 and U87 GBM in nude Balb/c), and syngeneic GBMs in immune-competent rodents (GL26 cells in C57BL/6 mice, CNS-1 cells in Lewis rats). All GBMs studied exhibited neovascularization, pleomorphism, vimentin immunoreactivity, and infiltration of T-cells and macrophages. All the tumors showed necrosis and hemorrhages, except the U87 human xenograft, in which the most salient feature was its profuse neovascularization. The tumors differed in the expression of astrocytic intermediate filaments: human and dog GBMs, as well as U251 xenografts expressed glial fibrillary acidic protein (GFAP) and vimentin, while the U87 xenograft and the syngeneic rodent GBMs were GFAP and vimentin+. Also, only dog GBMs exhibited endothelial proliferation, a key feature that was absent in the murine models. In all spontaneous and implanted GBMs we found histopathological features compatible with tumor invasion into the non-neoplastic brain parenchyma. Our data indicate that murine models of GBM appear to recapitulate several of the human GBM histopathological features and, considering their reproducibility and availability, they constitute a valuable in vivo system for preclinical studies. Importantly, our results indicate that dog GBM emerges as an attractive animal model for testing novel therapies in a spontaneous tumor in the context of a larger brain.

AB - Although rodent glioblastoma (GBM) models have been used for over 30 years, the extent to which they recapitulate the characteristics encountered in human GBMs remains controversial. We studied the histopathological features of dog GBM and human xenograft GBM models in immune-deficient mice (U251 and U87 GBM in nude Balb/c), and syngeneic GBMs in immune-competent rodents (GL26 cells in C57BL/6 mice, CNS-1 cells in Lewis rats). All GBMs studied exhibited neovascularization, pleomorphism, vimentin immunoreactivity, and infiltration of T-cells and macrophages. All the tumors showed necrosis and hemorrhages, except the U87 human xenograft, in which the most salient feature was its profuse neovascularization. The tumors differed in the expression of astrocytic intermediate filaments: human and dog GBMs, as well as U251 xenografts expressed glial fibrillary acidic protein (GFAP) and vimentin, while the U87 xenograft and the syngeneic rodent GBMs were GFAP and vimentin+. Also, only dog GBMs exhibited endothelial proliferation, a key feature that was absent in the murine models. In all spontaneous and implanted GBMs we found histopathological features compatible with tumor invasion into the non-neoplastic brain parenchyma. Our data indicate that murine models of GBM appear to recapitulate several of the human GBM histopathological features and, considering their reproducibility and availability, they constitute a valuable in vivo system for preclinical studies. Importantly, our results indicate that dog GBM emerges as an attractive animal model for testing novel therapies in a spontaneous tumor in the context of a larger brain.

KW - CNS-1

KW - Dog

KW - GL26

KW - Glioma

KW - U251

KW - U87

UR - http://www.scopus.com/inward/record.url?scp=35449004503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35449004503&partnerID=8YFLogxK

U2 - 10.1007/s11060-007-9400-9

DO - 10.1007/s11060-007-9400-9

M3 - Article

C2 - 17874037

AN - SCOPUS:35449004503

VL - 85

SP - 133

EP - 148

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -